Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Public ClinicalTrials.gov record NCT02404441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT02404441
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 319 participants
Conditions and interventions
Conditions
Interventions
- PDR001 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2015
- Primary completion
- Jul 20, 2020
- Completion
- Jul 20, 2020
- Last update posted
- Aug 2, 2022
2015 – 2020
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins | Baltimore | Maryland | 21287-0013 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Oregon Health and Science University SC-10 | Portland | Oregon | 97239 | — |
| Sarah Cannon Research Institute SCRI RC | Nashville | Tennessee | 37203 | — |
| University of Texas MD Anderson Cancer Center MD Anderson PSC | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute Univ. of Utah HCI | Salt Lake City | Utah | 84112-0550 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02404441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2022 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02404441 live on ClinicalTrials.gov.